Skip to main content
OpenTrials
Completed

NCT Number: NCT00745264

Multi-Centre, Open-Label, Two Segment, Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise

* Comparison of the plasma PK after single use of 100 mg ketoprofen from Diractin®. 50 mg applied on 2 major joints to * 400 mg ketoprofen from Diractin® (100 mg applied to 4 joints - overexposure) * 100 mg and 400 mg ketoprofen from Diractin® used concomitant with heat application * 100 mg and 400 mg ketoprofen from Diractin® used concomitant with moderate exercise

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

X-pert Med GmbH, Jena, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All of the following criteria have to be met to include a subject in the study:
  • Understands nature and provision of the study
  • Have been informed about the study by the investigator and gave signed and dated informed consent prior to participation
  • Male and female subjects
  • Age 18-55 years
  • Subjects in good health as determined by the Investigator
  • Woman of childbearing potential using reliable methods of contraception with a low failure rate (i.e. less than 1% per year), e.g. implants, injectables, combined oral contraceptives, reliable intrauterine-devices, vasectomised/ infertile partner or surgically sterile (uterus removed or both tubes tied) or postmenopausal (at least 2 years without periods)

Exclusion criteria

  • 4.2.1 General Exclusion Criteria
  • Investigator or any other team member involved directly or indirectly in the conduct of the clinical trial
  • Subjects who are inmates of psychiatric wards, prisons, or other state institutions
  • Participation in another clinical trial within the last 30 days
  • Not willing to refrain from exposing target areas after treatment to excessive ultraviolet light (solar radiation or solarium)
  • Pregnancy or lactation

4.2.2 Medical History Related Exclusion Criteria

  • Known hypersensitivity or allergy (including photoallergy) to NSAID´s including ketoprofen, and ingredients used in pharmaceutical products
  • Alcohol or drug abuse
  • Malignancy within the past 2 years
  • Skin lesions, dermatological diseases or tattoo in the treatment area
  • Major surgery 3 months before enrolment
  • Impaired haematopoesis and coagulation
  • Gastric and duodenal ulcer and gastrointestinal bleedings
  • Systemic lupus erythematodes, mixed connective tissue disease
  • Major heart disease / uncontrolled hypertension
  • Hepatic failure with ALT and/or AST > 2.0 ULN
  • Renal failure with serum creatinine levels > 1.5 milligrams/deciliter (mg/dL)
  • Varicosis, thrombophlebitis and other vascular disorders of the lower extremities
  • Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-sceletal system of the lower limbs
  • HIV - Infection
  • Blood donation one (1) month before screening and during study
  • Hepatitis B and C
  • Asthma bronchiale

Treatment and study plan

Diractin

Drug

100 mg Ketoprofen to 2 joints

Sponsors and collaborators

Lead sponsor

IDEA AG

Industry

Registry information

Official study title

Multi-Centre, Open-Label, Two Segment, Parallel Group Study Comparing Plasma Pharmacokinetics of Ketoprofen in Diractin® Alone to Diractin® Applied Concomitant With Heat or Moderate Exercise

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Sep 3, 2008
Registry last updated
Mar 20, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.